Amgen faces EU withdrawal of Tavneos (AMGN:NASDAQ)

Amgen (AMGN) is facing a possible EU withdrawal of its rare-disorder therapy, Tavneos, after an expert panel of the European Medicines Agency recommended its marketing authorization be revoked due to data integrity issues.

Also Read

Micron falls 5% in premarket, paring earlier gains amid tech rout

Piper Sandler initiates Connect Biopharma stock with overweight rating

SpaceX FOMO is officially over. Space stocks across the board are getting punished.

Plugin developed by ProSEOBlogger. Get free gpl themes.

The decision came after the EMA’s human